New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) Pre-clinical results showed that the novel in vivo anti-GPC3 ...
PHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (CARM) (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results